item management s discussion and analysis of financial condition and results of operations general the following discussion and analysis should be read in conjunction with the financial statements and notes thereto appearing elsewhere in this report 
the following table sets forth  for all periods indicated  the percentage relationship that items in the company s statements of operations bear to net sales 
year ended april  net sales cost of sales gross profit selling  general and administrative expense research and development costs contract research income interest expense interest income and other total expenses income before tax provision income tax provision net income results of operations years ended april  and for the fiscal year ended april  fiscal  net sales increased by  or to  from  for the fiscal year ended april  fiscal 
the increase was primarily the result of the increased shipments to our existing customers as well as several new customers in fiscal generic pharmaceutical products  which include private label contract manufacturing  had net sales for fiscal of  an increase of  or  compared to the fiscal respective period  and  for fiscal no one product accounted for sales of or more of total sales for each respective period 
health care products division  which markets the company s branded products  for fiscal and had net sales of  and  respectively  and  for fiscal sales of the health care products division increased modestly as a result of a mild cold and flu season 
cost of sales  as a percentage of net sales  increased from for fiscal to for fiscal in the generic drug industry  certain products may contribute significantly to a company s gross profit 
the gross profit on these products may change as market conditions change 
in the aggregate  the costs  as a percentage of sales  for materials increased and labor and overhead decreased 
units shipped increased and the average unit selling price increased which resulted from changes in product mix and competitive conditions 
if one or more other generic pharmaceutical manufacturers significantly reduce their prices in an effort to gain market share  the company s profitability could be adversely affected 
selling  general and administrative expenses  as percentage of net sales decreased from to  or decreased to  for fiscal from  for fiscal  a decrease of  resulting principally from reduced advertising and promotion expenditures for the health care products division as a result of a mild cold and flu season 
research and development costs increased to  or of sales for fiscal from  or of sales for fiscal as a result of  among other things  expenses associated with the filing of abbreviated new drug applications andas with the fda as well as development of new products for the company s health care products division 
many of the company s pharmaceutical products do not require prior approval before marketing 
however  certain products which the company introduced and intends to introduce under its product development program will require prior fda approval using the anda procedure before they can be manufactured and marketed 
such products include products to be manufactured in the company s sterile facility 
net income increased to  for fiscal from net income of  for fiscal  as a result of the factors noted above 
results of operations years ended april  and for fiscal  net sales increased by  or to  from  for the fiscal year ended april  fiscal 
the increase was primarily the result of the increased shipments to our existing customers as well as several new customers in fiscal sales of the health care products division declined approximately  cost of sales  as a percentage of net sales  decreased from for fiscal to for fiscal in the generic drug industry  certain products may contribute significantly to a company s gross profit 
the gross profit on these products may change as market conditions change 
in the aggregate  labor and overhead including the sterile manufacturing facility  expense increased less than increased sales 
primarily  a higher proportion of revenues from certain higher gross profit products influenced the results favorably 
if one or more other generic pharmaceutical manufacturers significantly reduce their prices in an effort to gain market share  the company s profitability could be adversely affected 
selling  general and administrative expenses  as percentage of net sales increased from to  or increased to  for fiscal from  for fiscal resulting principally from an increased sales staff and test mailing a product catalog to direct mail prospects 
research and development costs increased to  or of sales for fiscal from  or of sales for fiscal as a result of  among other things  expenses associated with the filing of andas with the fda as well as development of new products for the company s health care products division 
many of the company s pharmaceutical products do not require prior approval before marketing 
however  certain products which the company introduced and intends to introduce under its product development program will require prior fda approval using the anda procedure before they can be manufactured and marketed 
such products include products to be manufactured in the company s sterile facility 
net income increased to  for fiscal from net income of  for fiscal  as a result of the factors noted above 
liquidity and capital resources the company s operations are historically financed principally by cash flow from operations and bank borrowing 
at april  and april   working capital was approximately  and  respectively 
accounts payable increased from  for fiscal to  for fiscal due principally to a greater level of business during the fourth fiscal quarter and the aging of days of payables increasing 
accrued expenses decreased from  for fiscal to  for fiscal as a result of the decreased levels of selling price concessions 
cash flows from operating activities were approximately  which was the result principally of net income and depreciation of  cash flows used in investing activities was approximately  from operating activities funds and was principally payments for fixed assets acquired 
cash flows from financing activities approximated  and resulted principally from the exercise of incentive stock options which generated  in new capital 
on february  the company renewed its  working capital credit line which expires january  at april  the rate for borrowing was and there was no balance outstanding 
borrowings under the line are collateralized by inventory  accounts receivable and all other assets 
the agreement contains covenants with respect to working capital  net worth and certain financial ratios  as well as other covenants and prohibits the payment of cash dividends 
the company is responsible for all operating costs of its leased facility and has exercised its option to purchase the premises at the end of the lease in january for  the company believes that its financial resources consisting of current working capital  anticipated future operating revenue and its credit line will be sufficient to enable it to meet its working capital requirements for at least the next months 
in august  the financial accounting standards board fasb issued sfas no 
 accounting for the impairment or disposal of long lived assets 
sfas addresses financial accounting and reporting for the impairment or disposal of long lived assets 
sfas is effective for fiscal years beginning after december   and interim periods within those fiscal years with early application encouraged 
management has not determined the effect  if any  to the company s financial position or results of operations upon adoption of sfas in june  the fasb issued sfas  accounting for asset retirement obligations 
sfas requires that the fair value of a liability for an asset retirement obligation be recognized in the period in which it is incurred if a reasonable estimate of fair value can be made 
the provisions of sfas are effective for financial statements issued for fiscal years beginning after june  in june  the fasb issued sfas no 
 business combinations  and sfas no 
 goodwill and other intangible assets 
sfas required that the purchase method of accounting be used for all business combinations subsequent to june  and specific criteria for recognizing intangible assets acquired in a business combination 
under sfas no 
 the company will be required to re assess the goodwill and other intangible assets previously recorded in connection with prior acquisitions  as well as their useful lives 
sfas no 
requires that goodwill and intangible assets with indefinite useful lives no longer be amortized  but instead be tested for impairment at least annually 
whenever there is an impairment indicator  all acquired goodwill must be assigned to reporting units for purposes of impairment testing and segment reporting 
effective january   goodwill will no longer be subject to amortization 
intangible assets with definite useful lives will continue to be amortized over their respective lives 
management does not anticipate that adoption of these standards will have a material impact on our financial position or results of operations 
in may  the company announced a stock buy back program under which the board of directors authorized the purchase of up to  of its common stock 
in august the company increased the stock buy back program to an aggregate of  as of april  the company had purchased  shares at a cost of  
